No5 barrister at the head of the debate on pricing of rare drugs

Wed, 17 Nov 2010

No5 barrister David Lock is quoted in this week’s edition of the British Medical Journal in connection with the controversy over the pricing of rare drugs, which has seen 20 leading doctors write in protest to the Prime Minister about the conduct of drug companies.
 
Drug companies are attempting to persuade the NHS to prescribe expensive drugs which have an EU “marketing authorisation” in preference to much cheaper, generic drugs which have a similar clinical effect but have no marketing authorisation.
 
David has given advice to the NHS, which the NHS then chose to publish, that it would be likely to be lawful for NHS bodies to refuse to allow doctors to prescribe branded drug where there is a generic drug which delivers similar clinical outcomes at a lower cost. 
 
 

Related articles

The Supreme Court will today start hearing the appeal in the case of XX v Whittington Hospital NHS Trust. The case concerns whether a claimant can recover the costs of surrogacy utilising different methods both within England and Wales but also utilising commercial surrogacy arrangements in California....

Date: Mon, 16 Dec 2019
Counsel from No5 Barristers’ Chambers have successfully represented two officers who were alleged to have discriminated against a member of a public by reason of his race....

Date: Thu, 12 Dec 2019
Counsel from No5 Barristers’ Chambers prosecuted and defended (Mike Duck QC prosecuting and Ian Bridge defending) in the recent high profile and tragic case involving the death of Dr Suzanna Bull....

Date: Wed, 11 Dec 2019